Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...

10x Genomics disclaims any intention or obligation ... I'll start with the product innovations we introduced in 2024. First on our Chromium platform. Last year was the biggest year of Chromium ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...

Chromium Consumables Revenue (Q4 2024): $97.7 million ... Revenue Guidance (2025): $610 million to $630 million, representing ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...